...
首页> 外文期刊>International Journal of Pharmaceutics >Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme.
【24h】

Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme.

机译:合成的纳米低密度脂蛋白作为多形性胶质母细胞瘤的靶向药物递送载体。

获取原文
获取原文并翻译 | 示例

摘要

The low density lipoprotein (LDL) receptor has been shown to be upregulated in GBM tumor cells and is therefore a potential molecular target for the delivery of therapeutic agents. A synthetic nano-LDL (nLDL) particle was developed and tested to determine its utility as a drug delivery vehicle targeted to GBM tumors. nLDL particles were constructed by combining a synthetic peptide containing a lipid binding motif and the LDL receptor (LDLR) binding domain of apolipoprotein B-100 with a lipid emulsion consisting of phosphatidyl choline, triolein, and cholesteryl oleate. Composition analysis, fast protein liquid chromatography, and electron microscopy revealed that nLDL was highly reproducible and intermediate in size between high density lipoprotein and LDL particles (10.5+/-2.8 nm diameter). The binding and uptake of fluorescently labeled nLDL particles was assessed using fluorescence microscopy. Uptake of nLDL was time dependent, exhibiting saturation at approximately 3 h, and concentration dependent,exhibiting saturation at concentrations greater than 5 microM peptide. Using Lysotracker as a cellular marker, nLDL co-localized with lysosomes. nLDL binding was eliminated by blocking LDLRs with suramin and nLDL inhibited binding of plasma LDL to LDLRs. Collectively these data strongly suggest that the synthetic nano-LDLs described here are taken up by LDLR and can serve as a drug delivery vehicle for targeting GBM tumors via the LDLR.
机译:低密度脂蛋白(LDL)受体已显示在GBM肿瘤细胞中被上调,因此是治疗剂传递的潜在分子靶标。开发并测试了合成的纳米LDL(nLDL)颗粒,以确定其作为靶向GBM肿瘤的药物传递载体的效用。通过将包含脂质结合基序和载脂蛋白B-100的LDL受体(LDLR)结合结构域的合成肽与由磷脂酰胆碱,三油精和胆固醇油酸酯组成的脂质乳剂结合,构建nLDL颗粒。组成分析,快速蛋白质液相色谱和电子显微镜检查显示,nLDL可高度重现,并且大小介于高密度脂蛋白和LDL颗粒(直径10.5 +/- 2.8 nm)之间。使用荧光显微镜评估荧光标记的nLDL颗粒的结合和摄取。 nLDL的吸收是时间依赖性的,在约3 h时表现出饱和,而浓度依赖性,在浓度大于5 microM肽时表现出饱和。使用Lysotracker作为细胞标记,nLDL与溶酶体共定位。 nLDL结合通过用苏拉明阻断LDLR而消除,nLDL抑制血浆LDL与LDLR的结合。这些数据共同表明,此处描述的合成纳米LDL被LDLR吸收,并且可以用作通过LDLR靶向GBM肿瘤的药物递送载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号